

115

Fig 1A

5'-UTS →

5-GACCTAGAT CCAAGATCT CCAAGGATTT GGTGGCATA CCACTCCAGC ACACAGAAAGC ATGAGGTTCA

start codon

exon 1

intron 1

exon 2

TGACTCTCCT CTTCTGACA GCTCTGGCAG GAGCCCTGGT CTGTGCCT ↑ AT GATCCAGAGG CCGCCTCTGC

intron 2

exon 3

CCCAGGATCG GGGAAAC ↑ CTT GCCATGAAGC ATCAGCAGCT CAAAAGGAAA ATGCAGGTGA AGACCCAGGG

intron 3

exon 4

TTAGCCAGAC AGGCACCAA GCCAAGGAAG CAGAGATCCA GCCTTCTGG ↑ A AAAAGGCCTA GACGGAGCAA

intron 4

exon 5

stop codon

AAAAGCTGT GGGGGGACTC GGAAAACTAG GAAAAGATGC AGTCGAAGAT CTAGAAAGCG TGGGTAAAG ↑

AGCCGTCCAT GACGTTAAAG ACGTCCTTGA CTCAGTACTA TAGCTGTAAG GAGAAAGTGA GAAATGATAC

← 3'-UTS


CCAGGAGCAG CAGGCCTTTAC GTTTTCAGCC TAAACCT

Fig 1B

MRFM TLLFLT ALAGALVCAY DPEAASAPGS GNPCHESAA QKENAGEDPG LARQAPKPRK QRSSLLEKGL
DGAKKAVGGL KGLGKDAVED LESVGKGAVH DVKDVLDSVL


215

Fig. 2



3/5

Fig. 3



ANTIMICROBIALY ACTIVE PEPTIDE


Garbe, et al.

Appl. No.: Unknown

Atty Docket: WWELL73.008C1

4/5

Fig. 4



5/5

